Randomised controlled phase-2 trial to determinate the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia (HINKL)

• Applicant: Professor Dr. Martin Bornhäuser
• Subject Area: Hematology, Oncology
• Term: from 2012 to 2016
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 201928048

No abstract available

Publications

• 2013. Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation. Blood Cancer J 3:e136
  Schönefeldt, C.; Sockel, K.; Wehner, R.; Sopper, S.; Wolf, D.; Wermke, M.; Thiede, C.; Oelschlägel, U.; Ehninger, G.; Bornhäuser, M.; Platzbecker, U. & Schmitz, M.
  
• 2014. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts. Ann Hematol 93:1579–1586
  Michaelis, Sebastian U.; Mezger, Markus; Bornhäuser, Martin; Trenschel, Rudolf; Stuhler, Gernot; Federmann, Birgit; Oevermann, Lena; Kanz, Lothar; Handgretinger, Rupert & Bethge, Wolfgang A.